Galectin Therapeutics Announces Acceptance of Three Abstracts for the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting

Core Insights - Galectin Therapeutics, Inc. announced that three abstracts from its ongoing Phase 2b/3 NAVIGATE trial have been accepted for presentation at the AASLD's annual meeting in November 2024 [1][2] Group 1: Clinical Data Presentation - The three posters will be presented during the "Portal Hypertension and Other Complications of Cirrhosis" session on November 18, 2024 [2] - The titles of the abstracts include evaluations of esophageal and gastric varices, baseline patient characteristics from the NAVIGATE trial, and findings related to esophageal varices in patients with compensated MASH cirrhosis [2] Group 2: Company Overview - Galectin Therapeutics focuses on developing therapies for chronic liver disease and cancer, with its lead drug belapectin targeting galectin-3 protein [4] - The company is advancing its lead development program in metabolic dysfunction-associated steatohepatitis (MASH) with cirrhosis, which represents a significant medical need and drug development opportunity [4] - Additional development programs include combination immunotherapy for advanced head and neck cancers, with progress dependent on finding suitable partnerships [4]